Investor Presentaiton
IBI-322 (PD-L1/CD47): A First-in-Class Anti-PD-L1/CD47
Bispecific Antibody
IBI-322 Differentiated Advantages
Manageable safety profiles with reduced CD47 binding on
RBC to mitigate anemia AE and decreased RBC phagocytosis
due to weak CD47 blockade activity
• Improved DMPK profiles with reduced peripheral CD47
mediated sink effect and Optimized biodistribution and
enhanced PD-L1+ tumor uptake
Pre-clinical Highlights
20
1. CD47+, PD-L1+ tumor cells were
subcutaneously implanted in MC38
tumor-bearing mice with CD47
knock-in
•
Clinical Highlights
Modified Fibonacci method was used in the dose escalation
design of all studies at present for the ongoing Phase 1 trial.
DLT were not observed in all dose groups
Incidence and degree of anemia were low.
Preliminary antitumor activity has been observed.
IBI-322 Development Program Overview
•
China
US
Started patient enrolment in Phase 1a/1b in advanced
malignancies in 2H 2020
Started patient enrolment in Phase 1a in advanced malignancies
in Feb 2021
Plan to publish preliminary Phase 1a study for advanced malignancies
at academic conference
Clinical
progress
2. 89Zr-labeled IBI322, anti-CD47 mAb
and anti-PD-L1 mAb were
administrated intravenously at
0.5mg/kg
After 24h of scanning, IBI322 was found to be highly distributed in CD47+ PD-L1+
subcutaneous tumor tissues, which proved IBI322 had a strong targeting ability
2021 plan
•
Plan to enter Phase 1b trial in China and get preliminary PoC data
CD47/PDL1
CD47"
PDL1*
89Zr"
0
%ID/g
89Zr-DFO#
Innovent
First clinical stage PD-L1/CD47 bispecific under global development; Phase 1 trials ongoing in China and US.
Preliminary promising tolerability, safety and anti-tumor activity observed.
Confidential
Copyright©2021 Innovent Biologics
25
25View entire presentation